The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia

Launched by AMWAY (CHINA) R&D CENTER · Oct 10, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a product from Amway that is designed to lower uric acid levels in people with a condition called hyperuricemia. Hyperuricemia means that there is too much uric acid in the blood, which can lead to gout, a type of arthritis that causes painful swelling in the joints. The trial aims to see if using this product for three months can significantly reduce uric acid levels in participants aged 18 to 65 years.

To participate, individuals must be diagnosed with hyperuricemia and meet certain criteria, including having high uric acid levels on two separate occasions. They should not be taking any medications or supplements during the trial and must be willing to attend three study visits over the three months. Participants will be randomly assigned to one of three groups: two groups will receive the Amway product, while one group will receive a placebo (a non-active substance). Throughout the trial, researchers will carefully monitor and record all relevant health information to understand how well the product works. This study is currently recruiting participants, and those interested should ensure they meet the eligibility criteria before signing up.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants aged between 18 and 65 years old (mostly above 35 years old), including male and female and the ratio of male to female is not limited;
• • Patients with hyperuricemia: meet the diagnostic criteria set out in the "Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout (2019)", and fasting blood uric acid level exceeds 420 μmol/L twice on different days. Further classification using the Janssens Gout Diagnostic scale included asymptomatic hyperuricemia (that is, never had a gout attack) and patients with a history of gout, with a ratio of about 1:1;
• • Participants agree not to take any drugs, supplements, or performance enhancers during the study, or they will be eliminated
• • Participants understand the test procedure, read, and sign an appropriate Informed Consent Form indicating their willingness to participate.
• Exclusion Criteria:
• • Secondary gout caused by kidney disease, blood disease, drug use, tumor radiotherapy and chemotherapy;
• • Subjects who are using drugs during gout attacks;
• • Malignant diseases: patients with severe lung, cardiovascular, blood and hematopoietic system, central nervous system or other system diseases, as well as tumor patients;
• • Severe obesity (BMI\>32kg/m2);
• • Abnormal liver and kidney function: abnormal level of alanine aminotransferase or aspartate aminotransferase; Serum creatinine was higher than the upper limit of the normal range;
• • Allergic to the test drug or weak or allergic;
• • Pregnant or lactating women or those who have pregnancy plans; Sex hormone replacement therapy and oral contraception in the past 3 months;
• • Subjects who have participated in other research projects within three months;
• • Subjects that other researchers considered should be excluded.